Page last updated: 2024-08-05 12:00:53
hydroxypyrimidine
null
ChEBI ID: 38340
Members (16)
| Member | Definition | Role |
|---|---|---|
| 2-amino-6-methylpyrimidin-4-one | An aminopyrimidine compound having its amino group at position 2 and hydroxy and methyl substituents at positions 4 and 6 respectively. | 2-amino-4-hydroxy-6-methylpyrimidine; 2-amino-6-methylpyrimidin-4(3H)-one |
| 2-hydroxypyrimidine | The hydroxypyrimidine that is pyrimidine mono-substituted at C-2 by a hydroxy group. | pyrimidin-2-ol |
| 2,4-diaminohypoxanthine | 2,4-Diamino-6-hydroxypyrimidine | |
| 3-allyl-5-methyl-2-thioxo-2,3-dihydro[1,3]thiazolo[4,5-d]pyrimidin-7(6H)-one | 3-allyl-5-methyl-2-thioxo-2,3-dihydro[1,3]thiazolo[4,5-d]pyrimidin-7(6H)-one | |
| 4,6-dihydroxypyrimidine | 4,6-dihydroxypyrimidine | |
| 5-amino-6-ribitylamino-2,4-(1h,3h)pyrimidinedione | An aminouracil that is D-ribitol in which the hydroxy group at position 1 is substituted by the 6-amino group of 5,6-diaminouracil. Early intermediate in bacterial riboflavin synthesis. | 5-amino-6-(D-ribitylamino)uracil |
| 5-hydroxyuracil | 5-hydroxyuracil | |
| 6-hydroxy-2,4,5-triaminopyrimidine | A member of the class of aminopyrimidines that is 2,5,6-triaminopyrimidine carrying an additional hydroxy substituent at position 4. | 2,5,6-triamino-4-hydroxypyrimidine |
| 6-hydroxy-5-[(6-hydroxy-1-methyl-4-oxo-2-sulfanylidene-5-pyrimidinyl)-(2-pyridinyl)methyl]-1-methyl-2-sulfanylidene-4-pyrimidinone | 6-hydroxy-5-[(6-hydroxy-1-methyl-4-oxo-2-sulfanylidene-5-pyrimidinyl)-(2-pyridinyl)methyl]-1-methyl-2-sulfanylidene-4-pyrimidinone | |
| 6-Methyl-2-phenylpyrimidin-4-ol | 6-Methyl-2-phenylpyrimidin-4-ol | |
| argpyrimidine | A member of the class of hydroxypyrimidines obtained by cyclocondensation of L-arginine and methylglyoxal; a methyl glyoxal-derived advanced glycation end-product (AGE) in familial amyloidotic polyneuropathy and human cancers. | argpyrimidine |
| g 27550 | A hydroxypyrimidine that is pyrimidine substituted by an isopropyl group at position 2, a methyl group at position 6 and a hydroxy group at position 4. | 2-isopropyl-6-methyl-4-pyrimidinone; 2-isopropyl-6-methylpyrimidin-4-ol |
| isodialuric acid | A nucleobase analogue that is uracil substituted at positions 5 and 6 by hydroxy groups. | 5,6-dihydroxyuracil |
| n(5)-methyl-n(5)-formyl-2,5,6-triamino-4-hydroxypyrimidine | A pyrimidine derivative having amino substituents in the 2- and 6-positions, a hydroxy substituent at the 4-position and an N-methylformamido group at the 5-position. | 2,6-diamino-4-hydroxy-5-(N-methylformamido)pyrimidine |
| raltegravir | A pyrimidone that is pyrimidin-4(3H)-one in which the hydrogens at positions 2, 3, 5 and 6 are replaced by 2-[(5-methyl-1,3,4-oxadiazole-2-carbonyl)amino]propan-2-yl, methyl, hydroxy, and N-[(4-fluorophenyl)methyl]aminoacyl groups, respectively. It is an antiretroviral drug used for treatment of HIV infection. | raltegravir |
| thymine glycol | thymine glycol |
Research
Studies (498)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 55 (11.04) | 18.7374 |
| 1990's | 103 (20.68) | 18.2507 |
| 2000's | 150 (30.12) | 29.6817 |
| 2010's | 160 (32.13) | 24.3611 |
| 2020's | 30 (6.02) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 10 (1.78%) | 5.53% |
| Reviews | 17 (3.02%) | 6.00% |
| Case Studies | 1 (0.18%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 534 (95.02%) | 84.16% |